BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT06377735
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • BAI-BACE — PROCEDURE
    Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.

Study Details

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

Key Dates

First listed
Apr 22, 2024
Start date
May 1, 2024
Status verified
Aug 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2026

Study Design

Enrollment
85 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BAI-BACE
    Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI)

Primary Outcome Measure

Progression-Free-Survival (PFS) [ Time Frame: 12 months ]

Central Contacts

Find similar trials

Nationwide
Skin cancer trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies